StockNews.AI
BBNX
StockNews.AI
173 days

Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

1. BBNX will release Q4 and full-year 2024 results on March 25, 2025. 2. A conference call for performance review is scheduled post-announcement. 3. The iLet Bionic Pancreas is the first FDA-cleared automated insulin delivery device. 4. Beta Bionics aims to improve health outcomes for diabetes patients. 5. Investors can access the webcast and call details via the company's website.

Earnings
+3.7%Current Return
VS
-1.49%S&P 500
$19.9902/27 07:04 AM EDTEvent Start
$20.7302/28 01:51 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results may reflect strong performance, boosting investor confidence, similar to previous quarters where announcements led to positive movements in share prices.

How important is it?

The financial results and conference call will provide critical insights into BBNX's growth trajectory and investor sentiment, which are pivotal for pricing adjustments.

Why Short Term?

The immediate investor response to earnings reports typically influences short-term price movements, as seen in similar healthcare technology stocks.

Related Companies

MDGLDXCMISRG
February 27, 2025 07:00 ET  | Source: Beta Bionics, Inc. IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI8be51a4e688845529dd55d442f427c91. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com. Investor Relations:Blake BeberHead of Investor Relationsir@betabionics.com Media and Public Relations: Karen HynesVice President of Marketingmedia@betabionics.com Source: Beta Bionics, Inc.

Related News